Climb Bio, Inc. (CLYM) earnings date
Mar 5, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 35% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 40 days, typically, give or take 17 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | before open | 37 | 8-K |
| Q4 FY2025 | Thu, Mar 5, 2026 | before open | 64 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Tue, Aug 12, 2025 | before open | 43 | 8-K |
| Q1 FY2025 | Wed, May 14, 2025 | before open | 44 | 8-K |
| Q4 FY2024 | Tue, Mar 25, 2025 | after close | 84 | 8-K |
What they guided beta
| Q3 FY2026 | "Exhibit 99.1 Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates CLYM116 Phase 1 data in healthy volunteers showed sustained > 90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing Initiated dosing in NAVIGATE-2 Phase 2 trial of CLYM116 in IgAN; initial data expected in the first half of 2027" exhibit |
| Q3 FY2026 | "Initial PrisMN Phase 2 data for 200 mg budoprutug in pMN showed B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks; additional data from all cohorts, including longer-term follow-up, expected in 2027 Initial budoprutug Phase 1b data in SLE demonstrated a favorable safety and tolerability profile and dose-dependent B-cell depletion; additional Phase 1b data in ITP at American Society of Hematology in December 2026 $227.6 million in cash, cash equivalents and marketable securities as of September 30, 2026; expected cash runway into the second half of 2028 WELLESLEY HI" exhibit |
| Q3 FY2026 | "Anticipate initial NAVIGATE-2 data in the first half of 2027, and initiation of a global Phase 3 trial in 2027, pending regulatory feedback." exhibit |
| Q3 FY2026 | "Enrollment is ongoing in the third cohort (1000 mg), additional data from all cohorts, including longer-term follow-up, expected in 2027." exhibit |
| Q3 FY2026 | "Anticipate additional data from both ongoing studies in 2027." exhibit |
| Q2 FY2026 | "Exhibit 99.1 Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2026 Budoprutug clinical programs continue to advance, with data expected from pMN, ITP, and SLE studies in Q4 2026 Financing extends cash runway into the second half of 2028 WELLESLEY HILLS, Mass., August 6, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing" exhibit |
| Q2 FY2026 | "With our continued progress across our pipeline, and supported by our strengthened balance sheet, we are well positioned to continue to execute on our strategic priorities and rapidly advance both programs toward pivotal development, setting the stage for what we believe will be an exciting 2027 for Climb.”" exhibit |
| Q2 FY2026 | "Anticipate additional Phase 1 data at a medical meeting in the fourth quarter of 2026." exhibit |
| Q2 FY2026 | "The Phase 1/2 trial being conducted by the Company's partner, Beijing Mabworks Biotech Co., Ltd., is ongoing, with dosing of IgAN patients in the Phase 2 portion expected to begin in the third quarter of 2026." exhibit |
| Q2 FY2026 | "Anticipate initial Phase 1 data at an upcoming medical meeting, and initial Phase 2 data in 2027." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CLYM
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CLYM
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/CLYM/"><img src="https://veritasdata.dev/embed/CLYM.svg" alt="CLYM earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/CLYM/)
Script
<script async src="https://veritasdata.dev/embed/CLYM.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CLYM"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.